Form 4: Evolent Health Director Acquires Shares

Richard M. Jelinek, a Director at Evolent Health, Inc., acquired 41,096 shares of Class A Common Stock on June 4, 2026, as part of a restricted stock unit grant.

Summary

• Richard M. Jelinek, a Director of Evolent Health, Inc., acquired 41,096 shares of Class A Common Stock on June 4, 2026.
• This acquisition was made through a grant of restricted stock units (RSUs) under the company's 2015 Omnibus Incentive Compensation Plan.
• The acquired shares have a reported acquisition price of $0.
• Following this transaction, Mr. Jelinek beneficially owns 77,533 shares of Class A Common Stock, with 15,000 shares held indirectly by the Richard M. Jelinek Revocable Trust and another 15,000 shares held indirectly by the Richard M. Jelinek GST.
• The RSUs vest on the earlier of June 4, 2027, or the date of the company's 2027 annual meeting, contingent upon Mr. Jelinek's continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard equity compensation grant to a director rather than a purchase or sale of shares on the open market, which would typically carry more sentiment implications.

Positives

• Director acquisition of company stock can signal confidence in the company's future prospects.
• The acquisition of 41,096 shares by a director indicates a significant grant of equity compensation.
• The vesting schedule tied to continued service aligns management's interests with long-term company performance.

Negatives

• The acquisition was made through a stock grant with a $0 acquisition price, which is a form of compensation rather than an open market purchase.
• The filing does not provide information on the market value of the shares at the time of the grant or vesting.

Risks

• The vesting of the RSUs is contingent on continued service, meaning any departure before June 4, 2027, or the 2027 annual meeting could result in forfeiture of these shares.
• The overall market performance of Evolent Health, Inc. (EVH) could impact the value of these shares upon vesting.

Future Outlook

The restricted stock units granted to Richard M. Jelinek are set to vest on June 4, 2027, or the date of the Company's 2027 annual meeting, provided he remains in service.

Industry Context

StockSavvy.ai notes that insider transactions, such as this Form 4 filing by a director of Evolent Health, Inc., are common in the healthcare technology sector as a method of executive compensation and incentive alignment. The structure of the grant, tied to continued service and a future vesting date, is a standard practice aimed at retaining key personnel.

Stakeholder Impact

• Shareholders: The grant of RSUs represents a form of compensation that dilutes existing shareholders' ownership, though it is a standard practice for executive incentives.
• Employees: The continued service requirement for vesting aligns the director's interests with the company's long-term success, potentially benefiting all employees through improved company performance.
• Management: The grant serves as an incentive for the director to remain with the company and contribute to its strategic goals.

Next Steps

• Richard M. Jelinek will continue his service with Evolent Health, Inc. until the vesting date of June 4, 2027, or the 2027 annual meeting.
• The company will continue to operate under its 2015 Omnibus Incentive Compensation Plan.

Key Dates

Keywords

Evolent Health, EVH, Form 4, Insider Trading, Stock Grant, Restricted Stock Units, Director, Beneficial Ownership, Class A Common Stock, SEC Filing